30% royalties are huge.
Looking forward to US licensing deal to conclude. Should be a very big one.
Dimerix continues to negotiate the non-binding term sheets received for licensing opportunities with potential partners outside the Taiba (United Arab Emirates (UAE), Saudi Arabia, Oman, Kuwait, Qatar, Bahrain and Iraq) and Advanz Pharma (EEA, Canada, Switzerland, UK, Australia and New Zealand) territories, with a key focus being the major markets of US and China.
Ann: Dimerix and Taiba enter into License Agreement for DMX-200, page-70
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
43.5¢ |
Change
0.005(1.16%) |
Mkt cap ! $239.5M | |||
| Open | High | Low | Value | Volume |
| 42.5¢ | 44.3¢ | 42.5¢ | $634.3K | 1.458M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9998 | 43.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 44.5¢ | 26920 | 2 |
View Market Depth
| Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
| DXB (ASX) Chart |